title: Protection against cervical cancer versus decreasing harms from screening - What would U.S. patients and clinicians prefer, and do their preferences matter?
abstract: The primary goal for many providers in the United States has been to deliver the level of protection against cervical cancer afforded by annual cervical cytology while improving screening test performance. Adoption of recent screening recommendations has been inconsistent and has created considerable consternation and confusion. This editorial addresses the perspective of U.S. patients and providers and how their preferences may run counter to current screening recommendations.
authors.affiliation: Department of Women's Health, The Permanente Medical Group, 650 Response Road, Sacramento, CA 95815, USA. Electronic address: walter.kinney@kp.org.
authors.forename: Walter K
authors.initials: WK
authors.lastname: Kinney
authors.affiliation: Division of Gynecologic Oncology, University of Alabama at Birmingham, 1700 6th Avenue South, WIC Room 10250, Birmingham, AL, USA. Electronic address: whuh@uabmc.edu.
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
mesh_terms: D001291:Attitude of Health Personnel; D005260:Female; D040261:Harm Reduction; D006801:Humans; D027383:Papillomaviridae / Q000302:isolation & purification; D057240:Patient Preference; D011315:Preventive Medicine; D013997:Time Factors; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000517:prevention & control* / Q000821:virology
keywords: Cancer; Cervix; HPV; Screening